Atacand candesartan cilexetil regulatory update

FDA began a review to evaluate the possible risk of cancer in patients taking angiotensin II receptor inhibitors based on a study published in the Lancet suggesting a possible association. The study, which involved a meta-analysis from 9 studies including 95,000 patients, suggested that angiotensin-receptor blockers (ARBs) may be linked with a modestly increased risk of new cancer diagnosis (see BioCentury, June 21). The agency noted that it believes the benefits of ARBs continue to outweigh potential risks. ...